Objective To explore the effects of ⁶⁸gallium-labelled prostate-specific membrane antigen (PSMA) ligand PSMA-11 (⁶⁸Ga-PSMA-11) positron emission tomography-computed tomography (PET-CT) in the management of prostate cancer at different stages. Methods The clinical data of 386 prostate cancer patients who underwent ⁶⁸Ga-PSMA-11 PET-CT in Changhai Hospital of Naval Medical University (Second Military Medical University) from Jan. 31 to Dec. 31, 2019 were collected. We retrospectively analyzed the role of ⁶⁸Ga-PSMA-11 PET-CT in detection of metastases or local invasion for untreated patients, patients undergoing radiotherapy and/or hormonal therapy, and postoperative patients with persistent prostate-specific antigen (PSA) elevation or biochemical recurrence. The incidence rates of total metastasis, regional lymph node metastasis, prostate bed invasion, extracapsular invasion of the prostate, bone metastasis, and non-regional lymph node and/or organ metastases were analyzed. Results Among the 160 untreated patients, 44.4% (71/160) had metastases. In the 71 untreated patients with PSA ≥ 30 ng/mL, 69.0% (49/71) had metastases or local invasion, of which 50.7% (36/71) had bone metastases. In the 157 patients undergoing radiotherapy and/or hormonal therapy, 68.2% (107/157) had metastases or local invasion, of which 32.5% (51/157) had regional lymph node metastases, 9.6% (15/157) had prostate bed invasion, 47.1% (74/157) had bone metastases, and 19.7% (37/157) had non-regional lymph nodes and/or organ metastases. Among the 69 postoperative patients with persistent PSA elevation or biochemical recurrence, 52.2% (36/69) had metastases or local invasion, of which 17.4% (12/69), 11.6% (8/69), and 5.8% (4/69) only had regional lymph nodes, bone, and non-regional lymph node and/or organ metastases, respectively; 2.9% (2/69) only had prostate bed invasion, 10.1% (7/69) had regional lymph node and bone metastases, 2.9% (2/69) had bone and non-regional lymph node and/or organ metastases, and 1.4% (1/69) had regional lymph node and non-regional lymph node and/or organ metastases. Conclusion For untreated prostate cancer patients with PSA ≥ 30 ng/mL, ⁶⁸Ga-PSMA-11 PET-CT is recommended for preoperative evaluation; for patients undergoing radiotherapy and/or hormonal therapy, it can be used to monitor the progression of prostate cancer; and for postoperative patients with persistent PSA elevation or biochemical recurrence, it is recommended to detect metastasis.